Kim Smith, ViiV R&D chief
With competitors circling, ViiV wins another label update for long-acting HIV injectable Cabenuva
Just over a year after it was initially approved, GSK’s HIV unit ViiV Healthcare has found yet another way to make Cabenuva’s label even more …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
